Enrolling until December 31, 2025

The Department of Dermatology at the Mount Sinai School of Medicine in New York City is enrolling children and adults with alopecia areata (all types) in two studies. The investigational drugs are dupilumab and ritlecitinib.

Study #1 with dupilumab (Dupixent)

Investigational drug Dupixent (dupilumab) for ages 6 to adult.

Trial Criteria

This trial tests the use of dupilumab (Dupixent) for the treatment of alopecia areata.

• Enrolled patients are to be from age 6+. For patients age 6-17, we require an overall minimum of 30% hair loss from the scalp, and for patients age 18+ we require an overall minimum of 50% hair loss from the scalp.
• Patients are required to have a personal history of atopic disease (history of allergies, asthma, or eczema).
• Patients should not have tried Dupixent before.
• Patients are to self-administer subcutaneous injections of Dupixent weekly and return to our clinic every 8-12 weeks throughout the study.
• Additional item

Of note, there is a 33% chance of being randomized into a placebo group, but after 48 weeks everyone in the study is guaranteed to be receiving Dupixent.

General Information

Below is general information for alopecia areata studies at Mount Sinai.

• All patient data is anonymized, maintained strictly confidential, and restricted to the research office at the Department of Dermatology at Mount Sinai.
• Patients are compensated for their time in our studies upon completion.
• Patient data is aggregated and intended to be published in medical literature at a future time which could be one or more years from now.
• During visits, patients’ alopecia will be assessed, standard blood draws are done (not every visit), and medication will be administered and renewed.
• Each study has specific criteria including age, gender and duration of alopecia.

Patient Visit Location

Department of Dermatology
Icahn School of Medicine at Mount Sinai
5 East 98th Street, 5th Floor
New York, NY 10029

Contact

For anyone interested in participating in one of our studies, we would love the opportunity to discuss further. We can be reached at (212) 241-3288, or at ariel.azhdam@mountsinai.org or hannah.malinosky@mountsinai.org.

 Study #2 with Investigational Drug ritlecitinib (Litfulo)

Investigational drug Litfulo (ritlecitinib) for ages 12 to adult.

Trial Criteria

This trial tests the use of Litfulo (ritlecitinib) for the treatment of alopecia areata.

• Enrolled patients will be from age 12+. We require an overall minimum of 50% hair loss from the scalp.
• This trial tests the use of Litfulo (ritlecitinib) for the treatment of alopecia areata. The ritlecitinib approved dose is 50 mg daily. In this study, patients are randomized to treatment groups, so they will receive either 50 mg daily or 100 mg daily. Thus, there is no chance of receiving a placebo and everyone is guaranteed to be receiving Litfulo.
• The duration of the study is 57 weeks. In 48 of the weeks, participants will be receiving treatment. There are 8 visits total to our clinic, spaced out every 4-12 weeks.

General Information

Below is general information for alopecia areata studies at Mount Sinai.

• All patient data is anonymized, maintained strictly confidential, and restricted to the research office at the Department of Dermatology at Mount Sinai.
• Patients are compensated for their time in our studies upon completion.
• Patient data is aggregated and intended to be published in medical literature at a future time which could be one or more years from now.
• During visits, patients’ alopecia will be assessed, standard blood draws are done (not every visit), and medication will be administered and renewed.
• Each study has specific criteria including age, gender and duration of alopecia.

To inquire or apply:

For anyone interested in participating in one of our studies, we would love the opportunity to discuss further. We can be reached at (212) 241-3288, or at ariel.azhdam@mountsinai.org or hannah.malinosky@mountsinai.org.
Dr. Ariel Azhdam and Dr. Hannah Malinosky

Visit Location

Department of Dermatology
Icahn School of Medicine at Mount Sinai
5 East 98th Street, 5th Floor
New York, NY 10029